Kelvin Shi

2.6k citations

36 papers · 1.7k indexed · 2 hit papers · h-index 12

Gastroenterology top 0.5%
- Gastrointestinal motility and disorders 10
- Gastrointestinal Tumor Research and Treatment 9
Orthopedics and Sports Medicine top 1%
- Sports injuries and prevention 3
Surgery top 2%
- Knee injuries and reconstruction techniques 5
- Total Knee Arthroplasty Outcomes 3
- Gastrointestinal disorders and treatments 2
Pulmonary and Respiratory Medicine top 10%
- Gastric Cancer Management and Outcomes 10
Pharmacy top 10%
Cognitive Neuroscience
- EEG and Brain-Computer Interfaces 3

Co-authors: Brian Joyce Chadwick C. Prodromos Yung Han Steven J. Shiff Bernard J. Lavins Harvey Schneier Jeffrey M. Johnston Anthony Lembo
Cited by: Gastroenterology Orthopedics and Sports Medicine Surgery
Partner nations: United States United Kingdom France

In The Last Decade

Kelvin Shi

33 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
2007 A Meta‐analysis of the Incidence of Anterior Cruciate Ligament Tears as a Function of Gender, Sport, and a Knee Injury–Reduction Regimen

Peers

Countries citing papers authored by Kelvin Shi

Since Specialization

Citations

This map shows the geographic impact of Kelvin Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelvin Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelvin Shi more than expected).

Fields of papers citing papers by Kelvin Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelvin Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelvin Shi. The network helps show where Kelvin Shi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kelvin Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kelvin Shi Line = papers co-authored together Kelvin Shi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	AADNet: Exploring EEG Spatiotemporal Information for Fast and Accurate Orientation and Timbre Detection of Auditory Attention Based on a Cue-Masked Paradigm Kelvin Shi,Xu Liu,Yuan Xue,Haijie Shang,Ruiting Dai,Hanbin Wang,Yunfa Fu,Ning Jiang,Jiayuan He	2025	2
2	Intermediary-guided windowed attention Aggregation network for fine-grained characterization of Major Depressive Disorder fMRI Xue Ming Yuan,Maozhou Chen,Peng Ding,Anan Gan,Kelvin Shi,Anmin Gong,Lei Zhao,Tianwen Li,Yunfa Fu,Yuqi Cheng	2024	0
3	Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). M. Rizwan Rizwan-ul-Haq Khawaja,Abdul Rafeh Naqash,Reva Schneider,Aditi Shastri,Maximilian Stahl,Justin C. Moser,Nagla Fawzy Abdel Karim,Yazan F. Madanat,Brian A. Jonas,Eytan M. Stein,Shirish M. Gadgeel,James McCloskey,Ashwin Gollerkeri,Rachelle Perea,Yogesh K. Chutake,Sagar Agarwal,Patrick Henrick,Kelvin Shi,Naval Daver	2024	6
4	Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial Patrick Schöffski,Suzanne George,Michael C. Heinrich,John Zalcberg,Sebastian Bauer,Hans Gelderblom,César Serrano,Robin L. Jones,Steven Attia,Gina Z. D’Amato,Ping Chi,Peter Reichardt,Claus Becker,Kelvin Shi,Julie Meade,Rodrigo Ruiz‐Soto,Jean‐Yves Blay,Margaret von Mehren	2022	4
5	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour Suzanne George,Ping Chi,Michael C. Heinrich,Margaret von Mehren,Robin L. Jones,Kristen N. Ganjoo,Jonathan C. Trent,Hans Gelderblom,Albiruni Abdul Razak,Michael S. Gordon,Neeta Somaiah,Julia Jennings,Julie Meade,Kelvin Shi,Ying Su,Rodrigo Ruiz‐Soto,Filip Jankú	2021	22
6	1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study Margaret von Mehren,Michael C. Heinrich,Suzanne George,John Zalcberg,Sebastian Bauer,Hans Gelderblom,Patrick Schöffski,César Serrano,Robin L. Jones,Steven Attia,Gina Z. D’Amato,Ping Chi,Peter Reichardt,Julie Nicole Meade,V. Reichert,Kelvin Shi,Rodrigo Ruiz‐Soto,Jean‐Yves Blay	2021	10
7	1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study John Zalcberg,Michael C. Heinrich,Suzanne George,Sebastian Bauer,Hans Gelderblom,Patrick Schöffski,César Serrano,Robin L. Jones,Steven Attia,Gina Z. D’Amato,Ping Chi,Peter Reichardt,Julie Nicole Meade,V. Reichert,Kelvin Shi,Rodrigo Ruiz‐Soto,Margaret von Mehren,Jean‐Yves Blay	2020	1
8	O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS César Serrano,Michael C. Heinrich,Suzanne George,John Zalcberg,Sebastian Bauer,Hans Gelderblom,Patrick Schöffski,Robin L. Jones,Steven Attia,Gina Z. D’Amato,Ping Chi,Peter Reichardt,J. Meade,V. Reichert,Kelvin Shi,Jean‐Yves Blay,Margaret von Mehren	2020	4
9	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialbreakdown → Jean‐Yves Blay,César Serrano,Michael C. Heinrich,John Zalcberg,Sebastian Bauer,Hans Gelderblom,Patrick Schöffski,Robin L. Jones,Steven Attia,Gina Z. D’Amato,Ping Chi,Peter Reichardt,Julie Meade,Kelvin Shi,Rodrigo Ruiz‐Soto,Suzanne George,Margaret von Mehren	2020	251
10	Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib Ye Cheng,Fangling Du,Fengqi Fang,Z. J. DUAN,Wenhua Lei,Kelvin Shi	2020	11
11	INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) Margaret von Mehren,César Serrano,Sebastian Bauer,Hans Gelderblom,Suzanne George,Michael C. Heinrich,Patrick Schöffski,John Zalcberg,Ping Chi,Robin L. Jones,Peter Reichardt,Steven Attia,Gina Z. D’Amato,J. Meade,Kelvin Shi,Rodrigo Ruiz‐Soto,Jean‐Yves Blay	2019	14
12	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study David Planchard,Takashi Yokoi,Michael McCleod,Jürgen R. Fischer,Young‐Chul Kim,Marc Ballas,Kelvin Shi,Jean‐Charles Soria	2016	110
13	A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Satish S.C. Rao,Anthony Lembo,Steven J. Shiff,Bernard J. Lavins,Mark G. Currie,Xinwei D. Jia,Kelvin Shi,James E. MacDougall,James Shao,Paul Eng,Susan M. Fox,Harvey Schneier,Caroline B. Kurtz,Jeffrey M. Johnston	2012	293
14	Effects of Linaclotide on Abdominal and Bowel Symptoms Over the First Seven Days of Treatment in Patients with Irritable Bowel Syndrome with Constipation Lin Chang,Anthony Lembo,Steven J. Shiff,James Shao,Bernard J. Lavins,Kelvin Shi,Harvey Schneier,Mark G. Currie,Jeffrey Johnston	2012	1
15	Tu1423 Effects of Linaclotide on Straining Associated With Bowel Movements in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): A Post Hoc Analysis of Pooled Data From Two Phase 3 Trials Anthony Lembo,Satish S.C. Rao,Steven J. Shiff,Bernard J. Lavins,James E. MacDougall,Kelvin Shi,Harvey Schneier,Mark G. Currie,Jeffrey M. Johnston	2012	1
16	Tu1065 Comparison of Responder Rates and Degree of Agreement for Symptom-Specific and Global-Relief Endpoints in Two Phase 3 Trials of Linaclotide in IBS-C Giles R. Locke,Lin Chang,Mark G. Currie,Xinming Hao,Kelvin Shi,Harvey Schneier,Jeffrey M. Johnston	2012	1
17	Ti/Al Ohmic Contacts to n-Type GaN Nanowires Gangfeng Ye,Kelvin Shi,Robert A. Burke,Joan M. Redwing,Suzanne E. Mohney	2011	1
18	Magnetic Resonance Imaging Measurement of the Contralateral Normal Meniscus Is a More Accurate Method of Determining Meniscal Allograft Size Than Radiographic Measurement of the Recipient Tibial Plateau Chadwick C. Prodromos,Brian Joyce,Brett L. Keller,Brian J. Murphy,Kelvin Shi	2007	47
19	A Meta‐analysis of the Incidence of Anterior Cruciate Ligament Tears as a Function of Gender, Sport, and a Knee Injury–Reduction Regimenbreakdown → Chadwick C. Prodromos,Yung Han,Julie Rogowski,Brian Joyce,Kelvin Shi	2007	623
20	Vocational rehabilitation for outpatients with mental illness Z Wang,Hector W. H. Tsang,Kelvin Shi	2007	1

About Kelvin Shi

Kelvin Shi is a scholar working on Gastroenterology, Complementary and Manual Therapy and Pulmonary and Respiratory Medicine, having authored 36 papers that have together received 1.7k indexed citations. Recurring topics across this work include Gastrointestinal motility and disorders (10 papers), Gastric Cancer Management and Outcomes (10 papers), Gastrointestinal Tumor Research and Treatment (9 papers), Knee injuries and reconstruction techniques (5 papers), Total Knee Arthroplasty Outcomes (3 papers), EEG and Brain-Computer Interfaces (3 papers), Sports injuries and prevention (3 papers) and Gastrointestinal disorders and treatments (2 papers). The work is most often cited by research in Gastroenterology (589 citations), Orthopedics and Sports Medicine (684 citations) and Surgery (1.2k citations). Kelvin Shi has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Brian Joyce, Chadwick C. Prodromos, Yung Han, Steven J. Shiff, Bernard J. Lavins, Harvey Schneier, Jeffrey M. Johnston, Anthony Lembo, Mark G. Currie and James E. MacDougall.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact